Telix Pharmaceuticals Limited (NASDAQ: TLX) Stock Competitors & Peer Comparison
See TLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TLX | $11.94 | +1.70% | 4B | 124.63 | $0.10 | N/A |
| VRTX | $546.12 | -2.12% | 138.6B | 28.70 | $19.03 | N/A |
| REGN | $827.72 | -1.87% | 85.3B | 18.14 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,033.15 | -1.93% | 64.2B | 93.24 | $11.08 | N/A |
| MRNA | $145.55 | -2.23% | 57.8B | -17.86 | -$8.15 | N/A |
| RVMDW | $11.70 | -2.34% | 46.7B | -1.65 | -$7.21 | N/A |
| RVMD | $210.02 | -0.40% | 44.6B | -23.81 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.26 | -1.22% | 38.3B | 63.04 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TLX vs VRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while VRTX trades at $546.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas VRTX's P/E ratio is 28.70. In terms of profitability, TLX's ROE is +0.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TLX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TLX vs REGN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, REGN has a market cap of 85.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while REGN trades at $827.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas REGN's P/E ratio is 18.14. In terms of profitability, TLX's ROE is +0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
TLX vs VRNA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TLX's ROE is +0.07%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TLX vs ARGX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ARGX trades at $1,033.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ARGX's P/E ratio is 93.24. In terms of profitability, TLX's ROE is +0.07%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, TLX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
TLX vs MRNA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRNA has a market cap of 57.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MRNA trades at $145.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MRNA's P/E ratio is -17.86. In terms of profitability, TLX's ROE is +0.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TLX vs RVMDW Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RVMDW trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RVMDW's P/E ratio is -1.65. In terms of profitability, TLX's ROE is +0.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TLX vs RVMD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RVMD has a market cap of 44.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RVMD trades at $210.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RVMD's P/E ratio is -23.81. In terms of profitability, TLX's ROE is +0.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
TLX vs SGEN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TLX's ROE is +0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
TLX vs ONC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ONC trades at $358.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ONC's P/E ratio is 63.04. In terms of profitability, TLX's ROE is +0.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TLX vs ALNY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ALNY has a market cap of 35.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ALNY trades at $266.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ALNY's P/E ratio is 47.95. In terms of profitability, TLX's ROE is +0.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TLX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
TLX vs INSM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, INSM has a market cap of 27.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while INSM trades at $126.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas INSM's P/E ratio is -30.73. In terms of profitability, TLX's ROE is +0.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
TLX vs BNTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BNTX has a market cap of 26.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BNTX trades at $103.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BNTX's P/E ratio is -13.46. In terms of profitability, TLX's ROE is +0.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
TLX vs INCY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, INCY has a market cap of 25.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while INCY trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas INCY's P/E ratio is 17.04. In terms of profitability, TLX's ROE is +0.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TLX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INCY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TLX vs ROIV Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ROIV trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ROIV's P/E ratio is -33.23. In terms of profitability, TLX's ROE is +0.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TLX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ROIV's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TLX vs UTHR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, UTHR has a market cap of 20.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while UTHR trades at $487.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas UTHR's P/E ratio is 17.45. In terms of profitability, TLX's ROE is +0.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
TLX vs GMAB Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, GMAB has a market cap of 20.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while GMAB trades at $33.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas GMAB's P/E ratio is 25.32. In terms of profitability, TLX's ROE is +0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for TLX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TLX vs BGNE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TLX's ROE is +0.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TLX vs DNA-WT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TLX vs ASND Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ASND has a market cap of 16.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ASND trades at $270.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ASND's P/E ratio is -111.80. In terms of profitability, TLX's ROE is +0.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, TLX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TLX vs NBIX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while NBIX trades at $155.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas NBIX's P/E ratio is 22.49. In terms of profitability, TLX's ROE is +0.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TLX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TLX vs JAZZ Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while JAZZ trades at $246.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas JAZZ's P/E ratio is 9.23. In terms of profitability, TLX's ROE is +0.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TLX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for TLX.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TLX vs EXEL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while EXEL trades at $59.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas EXEL's P/E ratio is 16.86. In terms of profitability, TLX's ROE is +0.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TLX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EXEL's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TLX vs BBIO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BBIO has a market cap of 14.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BBIO trades at $74.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BBIO's P/E ratio is -20.01. In terms of profitability, TLX's ROE is +0.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TLX vs SMMT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while SMMT trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas SMMT's P/E ratio is -15.72. In terms of profitability, TLX's ROE is +0.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TLX vs HALO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while HALO trades at $110.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas HALO's P/E ratio is 20.56. In terms of profitability, TLX's ROE is +0.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TLX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TLX vs BMRN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BMRN trades at $66.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BMRN's P/E ratio is 31.99. In terms of profitability, TLX's ROE is +0.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TLX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TLX vs KRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TLX's ROE is +0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TLX vs MDGL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MDGL trades at $541.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MDGL's P/E ratio is -42.27. In terms of profitability, TLX's ROE is +0.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TLX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TLX vs ARWR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ARWR trades at $86.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ARWR's P/E ratio is -38.37. In terms of profitability, TLX's ROE is +0.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TLX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TLX vs TECH Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TECH trades at $72.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TECH's P/E ratio is 37.34. In terms of profitability, TLX's ROE is +0.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, TLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TLX vs RNAM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TLX's ROE is +0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TLX vs AXSM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while AXSM trades at $206.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas AXSM's P/E ratio is -53.96. In terms of profitability, TLX's ROE is +0.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, TLX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TLX vs KRYS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KRYS has a market cap of 10.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while KRYS trades at $358.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas KRYS's P/E ratio is 44.89. In terms of profitability, TLX's ROE is +0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TLX vs PRAX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PRAX has a market cap of 9.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PRAX trades at $351.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PRAX's P/E ratio is -27.21. In terms of profitability, TLX's ROE is +0.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TLX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TLX vs KYMR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while KYMR trades at $117.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas KYMR's P/E ratio is -36.68. In terms of profitability, TLX's ROE is +0.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TLX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TLX vs IONS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IONS has a market cap of 9.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while IONS trades at $58.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas IONS's P/E ratio is -33.77. In terms of profitability, TLX's ROE is +0.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IONS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TLX vs RXDX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TLX's ROE is +0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TLX vs PTGX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PTGX has a market cap of 9.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PTGX trades at $145.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PTGX's P/E ratio is 141.48. In terms of profitability, TLX's ROE is +0.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TLX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TLX vs NUVL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TLX's ROE is +0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NUVL's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TLX vs CYTK Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CYTK has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CYTK trades at $72.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CYTK's P/E ratio is -10.07. In terms of profitability, TLX's ROE is +0.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TLX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CYTK's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TLX vs CRNX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CRNX's P/E ratio is -16.86. In terms of profitability, TLX's ROE is +0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TLX vs PCVX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PCVX trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PCVX's P/E ratio is -8.02. In terms of profitability, TLX's ROE is +0.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TLX vs IMGN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TLX's ROE is +0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TLX vs TGTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TGTX trades at $55.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TGTX's P/E ratio is 20.28. In terms of profitability, TLX's ROE is +0.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TLX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TLX vs IBRX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while IBRX trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas IBRX's P/E ratio is -8.33. In terms of profitability, TLX's ROE is +0.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TLX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IBRX's competition here
Abivax S.A. (NASDAQ: ABVX)
TLX vs ABVX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ABVX trades at $114.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ABVX's P/E ratio is -60.17. In terms of profitability, TLX's ROE is +0.07%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TLX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TLX vs BPMC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TLX's ROE is +0.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TLX vs APGE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas APGE's P/E ratio is -31.19. In terms of profitability, TLX's ROE is +0.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TLX vs CERE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CERE's P/E ratio is -16.47. In terms of profitability, TLX's ROE is +0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TLX vs IMVT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while IMVT trades at $39.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas IMVT's P/E ratio is -13.92. In terms of profitability, TLX's ROE is +0.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TLX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
TLX vs TXG Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TXG has a market cap of 8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TXG trades at $62.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TXG's P/E ratio is -106.19. In terms of profitability, TLX's ROE is +0.07%, compared to TXG's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TLX vs TWST Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TWST trades at $124.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TWST's P/E ratio is -56.18. In terms of profitability, TLX's ROE is +0.07%, compared to TWST's ROE of -0.30%. Regarding short-term risk, TLX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TWST's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TLX vs BLTE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, BLTE has a market cap of 7.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while BLTE trades at $193.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas BLTE's P/E ratio is -103.53. In terms of profitability, TLX's ROE is +0.07%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, TLX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BLTE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TLX vs SYRE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while SYRE trades at $88.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas SYRE's P/E ratio is -45.63. In terms of profitability, TLX's ROE is +0.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
TLX vs MTSR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TLX's ROE is +0.07%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TLX vs CAI Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CAI trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CAI's P/E ratio is 70.44. In terms of profitability, TLX's ROE is +0.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CAI's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TLX vs RYTM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RYTM trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RYTM's P/E ratio is -33.04. In terms of profitability, TLX's ROE is +0.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
TLX vs MRUS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TLX's ROE is +0.07%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TLX vs ACLX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TLX's ROE is +0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TLX vs SRRK Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while SRRK trades at $55.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas SRRK's P/E ratio is -16.04. In terms of profitability, TLX's ROE is +0.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TLX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
TLX vs CGON Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CGON trades at $74.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CGON's P/E ratio is -27.76. In terms of profitability, TLX's ROE is +0.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TLX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TLX vs RETA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RETA's P/E ratio is -66.29. In terms of profitability, TLX's ROE is +0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TLX vs CNTA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TLX's ROE is +0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TLX vs MIRM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MIRM trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MIRM's P/E ratio is -6.93. In terms of profitability, TLX's ROE is +0.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TLX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MIRM's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TLX vs TVTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TVTX trades at $65.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TVTX's P/E ratio is -145.07. In terms of profitability, TLX's ROE is +0.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TLX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TLX vs DNTH Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while DNTH trades at $108.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas DNTH's P/E ratio is -26.05. In terms of profitability, TLX's ROE is +0.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TLX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TLX vs COGT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while COGT trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas COGT's P/E ratio is -16.47. In terms of profitability, TLX's ROE is +0.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, TLX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TLX vs PTCT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PTCT trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PTCT's P/E ratio is -29.74. In terms of profitability, TLX's ROE is +0.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TLX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTCT's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TLX vs XENE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while XENE trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas XENE's P/E ratio is -12.71. In terms of profitability, TLX's ROE is +0.07%, compared to XENE's ROE of -0.44%. Regarding short-term risk, TLX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TLX vs LGND Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while LGND trades at $285.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas LGND's P/E ratio is 31.35. In terms of profitability, TLX's ROE is +0.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LGND's competition here
Erasca, Inc. (NASDAQ: ERAS)
TLX vs ERAS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ERAS has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ERAS trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ERAS's P/E ratio is -17.41. In terms of profitability, TLX's ROE is +0.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ERAS's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TLX vs CDTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TLX's ROE is +0.07%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TLX vs ORKA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ORKA trades at $92.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ORKA's P/E ratio is -47.69. In terms of profitability, TLX's ROE is +0.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, TLX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
TLX vs ABCM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TLX's ROE is +0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TLX vs ISEE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TLX's ROE is +0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TLX vs CRSP Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CRSP trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CRSP's P/E ratio is -11.72. In terms of profitability, TLX's ROE is +0.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TLX vs APLS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas APLS's P/E ratio is 38.35. In terms of profitability, TLX's ROE is +0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TLX vs DFTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while DFTX trades at $38.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas DFTX's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TLX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DFTX's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
TLX vs ACAD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ACAD trades at $28.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ACAD's P/E ratio is 12.62. In terms of profitability, TLX's ROE is +0.07%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ACAD's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TLX vs TERN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TERN's P/E ratio is -51.41. In terms of profitability, TLX's ROE is +0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TERN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
TLX vs PBLS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PBLS has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PBLS trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PBLS's P/E ratio is -45.93. In terms of profitability, TLX's ROE is +0.07%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, TLX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PBLS's competition here
Celcuity Inc. (NASDAQ: CELC)
TLX vs CELC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CELC has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CELC trades at $95.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CELC's P/E ratio is -22.26. In terms of profitability, TLX's ROE is +0.07%, compared to CELC's ROE of -3.51%. Regarding short-term risk, TLX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TLX vs EWTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while EWTX trades at $43.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas EWTX's P/E ratio is -23.28. In terms of profitability, TLX's ROE is +0.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TLX vs FOLD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TLX's ROE is +0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TLX.Check FOLD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
TLX vs DYN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, DYN has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while DYN trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas DYN's P/E ratio is -7.54. In terms of profitability, TLX's ROE is +0.07%, compared to DYN's ROE of -0.64%. Regarding short-term risk, TLX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DYN's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TLX vs AKRO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TLX's ROE is +0.07%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TLX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TLX vs ALPN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TLX's ROE is +0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
TLX vs ELVN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ELVN trades at $59.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ELVN's P/E ratio is -35.52. In terms of profitability, TLX's ROE is +0.07%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, TLX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
TLX vs OPT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas OPT's P/E ratio is -1.52. In terms of profitability, TLX's ROE is +0.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TLX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
TLX vs PRTC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TLX's ROE is +0.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TLX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TLX vs RLAY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while RLAY trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas RLAY's P/E ratio is -12.13. In terms of profitability, TLX's ROE is +0.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, TLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TLX vs MRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TLX's ROE is +0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
TLX vs MANE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while MANE trades at $98.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas MANE's P/E ratio is -31.34. In terms of profitability, TLX's ROE is +0.07%, compared to MANE's ROE of -0.29%. Regarding short-term risk, TLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MANE's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TLX vs VKTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas VKTX's P/E ratio is -7.48. In terms of profitability, TLX's ROE is +0.07%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TLX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VKTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
TLX vs LEGN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while LEGN trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas LEGN's P/E ratio is -31.65. In terms of profitability, TLX's ROE is +0.07%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LEGN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
TLX vs IOVA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, IOVA has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while IOVA trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas IOVA's P/E ratio is -12.04. In terms of profitability, TLX's ROE is +0.07%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, TLX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IOVA's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
TLX vs TARS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, TARS has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while TARS trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas TARS's P/E ratio is -83.28. In terms of profitability, TLX's ROE is +0.07%, compared to TARS's ROE of -0.14%. Regarding short-term risk, TLX is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TARS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TLX vs ADPT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while ADPT trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas ADPT's P/E ratio is -59.22. In terms of profitability, TLX's ROE is +0.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TLX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TLX vs CPRX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.94 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 124.63, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TLX's ROE is +0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CPRX's competition here